SCHEMBL5149205

SCHEMBL5149205

CC(C)n1nc(-c2nc(N)c(C#N)nc2-c2ccccc2Br)ccc1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP8 P40818 8/20 0.51
USP7 Q93009 3/20 0.39
USP47 Q96K76 1/20 0.39
ADORA2A P29274 2/20 0.37
MYC P01106 1/20 0.35
WDR5 P61964 1/20 0.35
IKBKB O14920 2/20 0.31
MTOR P42345 4/20 0.31
PIK3CD O00329 3/20 0.31
ABL1 P00519 3/20 0.31
EGFR P00533 3/20 0.31
HCK P08631 3/20 0.31
SRC P12931 3/20 0.31
KDR P35968 3/20 0.31
PIK3CA P42336 3/20 0.31
PIK3CG P48736 3/20 0.31
EPHB4 P54760 3/20 0.31
PRKDC P78527 3/20 0.31
PI4KB Q9UBF8 1/20 0.31
ATR Q13535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149248 1.00 USP8 (0.51) USP8USP7USP47ADORA2AMYC
SCHEMBL5152779 0.93 USP8 (0.46) USP8USP7USP47MYCWDR5
SCHEMBL5147962 0.85 USP8 (0.46) USP8USP7USP47ADORA2AMTOR
SCHEMBL5147922 0.85 USP8 (0.46) USP8USP7USP47ADORA2AMTOR
SCHEMBL5147996 0.84 ADORA2A (0.36) USP8ADORA2AIKBKBFGFR1FGFR2
SCHEMBL5152934 0.82 ADORA2A (0.36) ADORA2AATR
SCHEMBL5150681 0.81 USP8 (0.34) USP8USP7USP47
SCHEMBL5150678 0.81 USP8 (0.34) USP8USP7USP47
SCHEMBL5152670 0.80 ADORA2A (0.38) ADORA2AMYCWDR5ATRFGFR1
SCHEMBL5151091 0.79 ADORA2A (0.43) USP8ADORA2AMTORPIK3CDABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
EP-1737841-A1 PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS Astellas Pharma Inc. (JP) 2007-01-03 EP disclosed
WO-2005095384-A1 PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS ASTELLAS PHARMA INC. (JP) 2005-10-13 WO disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 USP8 4814/4885USP7 4772/4885USP47 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.